Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$27,000.00
Development of a patient-administered oral pill for colorectal cancer screening
EF 2024-25
Résumé
Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer in Canada and the second leading cause of cancer deaths worldwide. If detected early, CRC is highly treatable, with 92% of patients being cured. Despite the importance of early detection, adherence to screening remains below national goals. Existing screening methods like colonoscopies are invasive and deter participation due to discomfort and logistical challenges with scheduling. Fecal immunochemical tests (FIT), a less invasive alternative, lack sensitivity for detecting precancerous polyps and face stigma related to stool handling. To address these limitations, this research leverages materials chemistry to develop a non-invasive, patient-administered biosensor in the form of a reactive oxygen species (ROS)-responsive hydrogel pill. Elevated ROS levels are associated with colorectal tumors and precancerous polyps, allowing them to serve as an ideal biomarker for CRC. The proposed device will release a fluorescent signal in the stool in the presence of elevated ROS, creating a visible signal of CRC without the need for stool manipulation. This project will involve synthesizing and tuning ROS-responsive hydrogels for optimal CRC sensitivity, then validating the hydrogel pill in a rat model of CRC and comparing its sensitivity to FIT. This novel hydrogel pill has the potential to significantly increase CRC screening accessibility and adherence, improving early detection rates and patient outcomes while reducing healthcare system burdens.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
530001
Name
Poulin Isabelle
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of a patient-administered oral pill for colorectal cancer screening
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomaterials; Biosensing; Cancer Detection; Colorectal Cancer
Abstract
Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer in Canada and the second leading cause of cancer deaths worldwide. If detected early, CRC is highly treatable, with 92% of patients being cured. Despite the importance of early detection, adherence to screening remains below national goals. Existing screening methods like colonoscopies are invasive and deter participation due to discomfort and logistical challenges with scheduling. Fecal immunochemical tests (FIT), a less invasive alternative, lack sensitivity for detecting precancerous polyps and face stigma related to stool handling. To address these limitations, this research leverages materials chemistry to develop a non-invasive, patient-administered biosensor in the form of a reactive oxygen species (ROS)-responsive hydrogel pill. Elevated ROS levels are associated with colorectal tumors and precancerous polyps, allowing them to serve as an ideal biomarker for CRC. The proposed device will release a fluorescent signal in the stool in the presence of elevated ROS, creating a visible signal of CRC without the need for stool manipulation. This project will involve synthesizing and tuning ROS-responsive hydrogels for optimal CRC sensitivity, then validating the hydrogel pill in a rat model of CRC and comparing its sensitivity to FIT. This novel hydrogel pill has the potential to significantly increase CRC screening accessibility and adherence, improving early detection rates and patient outcomes while reducing healthcare system burdens.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Poulin, Isabelle
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~